Switzerland roots its foundations in life sciences collaboration

BioXconomy highlights how Switzerland’s biotech sector leans on partnerships as a core growth engine—supported by proximity to major players like Roche, Novartis, and Lonza, and a talent base shaped by technical universities and vocational pathways. Insights from a Nordic Life Sciences Days panel suggest many companies choose Switzerland less for easy local fundraising and more for the infrastructure, people, and day-to-day ability to execute.

The piece also points to recent funding momentum from the Swiss Biotech Report (May 2025), including $3.1 billion raised in 2024 (CHF 2.5 billion) and about $877 million in the first half of 2025 (CHF 705 million). At the same time, speakers note that domestic risk capital can be constrained, with much venture funding coming from abroad—reinforcing the idea of Switzerland as a place to build and partner, while often looking internationally for scale-up capital.

Concrete Nordic ties underline the theme: Swiss-based Ferring Pharmaceuticals’ multi-year collaboration with Sweden’s Karolinska Institutet, and Lausanne-based Debiopharm’s backing of Nordic startups through financing rounds valued at $150 million. Overall, the article frames collaboration—across borders and through licensing and strategic alliances—as a default model for Swiss life sciences growth.

Read the full article on the original source (BioXconomy).